



Cells by Priming for
Tumor Necrosis Factor
α–Induced Necroptosis1,2
Bram Laukens*,†,‡,§,3, Claudia Jennewein*,3,
Barbara Schenk§, Nele Vanlangenakker†,‡,
Alexander Schier*, Silvia Cristofanon§,
Kerry Zobel¶, Kurt Deshayes¶, Domagoj Vucic¶,
Irmela Jeremias#, Mathieu J.M. Bertrand†,‡,
Peter Vandenabeele†,‡,4 and Simone Fulda*,§,4
*University Children’s Hospital, Ulm, Germany; †Department
for Molecular Biomedical Research, Flanders Institute for
Biotechnology, Zwijnaarde-Ghent, Belgium; ‡Department of
Biomedical Molecular Biology, Ghent University, Zwijnaarde-
Ghent, Belgium; §Institute for Experimental Cancer
Research in Pediatrics, Goethe-University, Frankfurt,
Germany; ¶Genentech, Inc, South San Francisco, CA, USA;
#Helmholtz Center Munich – German Research Center
for Environmental Health, Munich, Germany
Abstract
Searching for new strategies to bypass apoptosis resistance, we investigated the potential of the Smac mimetic BV6 in
Jurkat leukemia cells deficient in key molecules of the death receptor pathway. Here, we demonstrate for the first time that
Smac mimetic primes apoptosis-resistant, FADD- or caspase-8–deficient leukemia cells for TNFα-induced necroptosis in a
synergistic manner. In contrast to TNFα, Smac mimetic significantly enhances CD95-induced apoptosis in wild-type but
not in FADD-deficient cells. Interestingly, Smacmimetic- and TNFα-mediated cell death occurs without characteristic features
of apoptosis (i.e., caspase activation, DNA fragmentation) in FADD-deficient cells. By comparison, Smac mimetic and TNFα
trigger activation of caspase-8, -9, and -3 and DNA fragmentation in wild-type cells. Consistently, the caspase inhibitor zVAD.
fmk fails to block Smac mimetic- and TNFα-triggered cell death in FADD- or caspase-8–deficient cells, while it confers pro-
tection in wild-type cells. By comparison, necrostatin-1, an RIP1 kinase inhibitor, abolishes Smac mimetic- and TNFα-induced
cell death in FADD- or caspase-8–deficient. Thus, Smac mimetic enhances TNFα-induced cell death in leukemia cells via
two distinct pathways in a context-dependent manner: it primes apoptosis-resistant cells lacking FADD or caspase-8 to
TNFα-induced, RIP1-dependent and caspase-independent necroptosis, whereas it sensitizes apoptosis-proficient cells to
TNFα-mediated, caspase-dependent apoptosis. These findings have important implications for the therapeutic exploitation
of necroptosis as an alternative cell death program to overcome apoptosis resistance.
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Introduction
Apoptosis is a form of programmed cell death that typically leads
to caspase activation as a common effector mechanism and may
proceed via two major routes, namely, the death receptor (extrinsic)
and the mitochondrial (intrinsic) pathways [1]. Stimulation of
death receptors of the tumor necrosis factor (TNF) receptor super-
family on the cell surface, including CD95 (APO-1/Fas), TNF-
related apoptosis-inducing ligand (TRAIL) receptors, or TNF
receptor 1 (TNFR1), triggers caspase-8 activation in a multimeric
complex including the adaptor protein FADD, resulting in subsequent
cleavage of downstream effector caspases such as caspase-3 [2]. In the
mitochondrial pathway, cytochrome c and second mitochondria-
derived activator of caspase (Smac)/direct IAP binding protein with
low pI (DIABLO) are released from mitochondria into the cytosol,
which in turn triggers caspase-3 activation via the apoptosome com-
plex and via binding to X-linked inhibitor of apoptosis (XIAP),
respectively [3].
While necrosis has previously been viewed as an uncontrolled, ac-
cidental mode of cell death, it is now well appreciated that necroptosis
(programmed necrosis) is a regulated, caspase-independent form of cell
death that occurs when caspase activation is inhibited or absent [4]. The
serine/threonine kinase RIP1 has been identified as a critical mediator
of TNFα-initiated necroptosis that becomes phosphorylated on the
induction of necroptosis and interacts with RIP3 to form the necro-
some complex [5]. In addition, RIP1 is involved in the regulation of
apoptosis after death receptor ligation [6,7], implying that apoptotic
and necrotic pathways share some common components.
Inhibitor of apoptosis (IAP) proteins are a family of eight proteins,
which, per definition, all possess a baculovirus IAP repeat (BIR) domain
that mediates the binding and inhibition of caspases [8]. By compari-
son, only some IAP proteins, namely, XIAP, cellular inhibitor of
apoptosis 1 and 2 (cIAP1 and cIAP2), also harbor a RING domain with
E3 ubiquitin ligase activity that mediates (auto)ubiquitination and
proteasomal degradation [8]. XIAP is well characterized for its anti-
apoptotic activity through binding to and inhibiting caspase-9 and
-3/-7 via its BIR3 domain and the linker region preceding BIR2
domain, respectively [9]. Recently, cIAP1 and cIAP2 were identified
as E3 ubiquitin ligases for the serine/threonine kinase RIP1 that poly-
ubiquitinate RIP1 via K63-linked chains [10,11]. Depending on its
ubiquitination status, RIP1 either promotes survival by stimulating
nuclear factor κB activation once it is ubiquitinated or contributes to
cell death in its deubiquitinated form, which allows its interaction with key
components of death receptor signaling such as FADD and caspase-8 [5].
Smac mimetics have been shown to trigger autoubiquitination and
proteasomal degradation of IAP proteins with a RING domain including
cIAP1 and cIAP2 [12–14] and, thus, can indirectly favor deubiquitina-
tion of RIP1 [10].
Resistance to apoptosis represents a characteristic feature of human
cancers and represents a major unsolved obstacle in clinical oncology [15].
IAP proteins are expressed at high levels in many malignancies including
leukemia and contribute to evasion of apoptosis [16]. We previously re-
ported that IAP antagonists sensitize cancer cells to apoptosis and over-
come Bcl-2–imposed resistance to apoptosis by switching type II cells that
depend on the mitochondrial contribution to TRAIL-induced apoptosis
into type I cells, which signal to apoptosis irrespective of high Bcl-2
levels [17–19]. Searching for novel strategies to bypass cancer cell
resistance to apoptosis, we investigated in the present study whether




Human wild-type (WT) Jurkat T-ALL, FADD-deficient, caspase-
8–deficient, or caspase-8–deficient and Bcl-2–overexpressing variants
of human Jurkat clones deficient in FADD, caspase-8 or caspase-8–
deficient, and Bcl-2–overexpressing cells were kind gifts from Dr J.
Blenis or Dr S. Nagata [20–22]. Cells were cultured in RPMI 1640
medium supplemented with 10% fetal calf serum, 1 mM L-glutamine,
25 mM HEPES buffer, 50 U/ml penicillin, and 50 μg/ml streptomy-
cin. Leukemia blasts were derived from children treated for ALL at the
Ludwig Maximilians University’s Children’s Hospital after informed
consent was obtained in accordance with the Declaration of Helsinki.
The study was approved by the local ethical committee. Samples were
obtained by bone marrow puncture at initial diagnosis before the onset
of therapy, isolated using Ficoll Isopaque (Amersham Bioscience,
Freiburg, Germany) and stimulated directly after isolation. Smac
mimetic BV6 is a bivalent IAP antagonist compound [13]. Caspase
inhibitor N -benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
(zVAD.fmk) was obtained from Bachem (Heidelberg, Germany)
and TNFα and necrostatin 1 (Nec-1) were purchased from Biomol
(Hamburg, Germany). Enbrel was kindly provided by Pfizer. All
chemicals were purchased by Sigma (Steinheim, Germany) unless
indicated otherwise.
Western Blot Analysis and Immunoprecipitation
Western blot analysis was performed as described previously [23]
using the following antibodies: mouse anti–caspase-8 (1:1000) from
Alexis Biochemicals (Epalinges, Switzerland); rabbit anti–caspase-3
(1:1000) from Cell Signaling (Beverly, MA); rabbit anti–caspase-9
(1:1000), mouse anti-XIAP, and mouse anti-RIP1 (1:1000) from
BD Biosciences (Heidelberg, Germany); goat anti-cIAP1 (1:1000)
and rabbit anti-survivin (1:1000) from R&D Systems, Inc (Wiesbaden,
Germany); and rabbit anti-cIAP2 (1:1000) from Epitomics (Burlingame,
CA) or mouse anti–β-actin as loading control (1:5000) from Sigma fol-
lowed by goat-antimouse, goat-antirabbit, or donkey-antigoat IgG conju-
gated to horseradish peroxidase (1:5000) from Santa Cruz Biotechnology
(Santa Cruz, CA). Enhanced chemiluminescence was used for detec-
tion (Amersham Bioscience). Immunoprecipitation was performed as
described previously [10].
Determination of Cell Death
Apoptosis was determined by fluorescence-activated cell sorting
analysis (FACScan; BD Biosciences) of DNA fragmentation of pro-
pidium iodide–stained nuclei or by forward side scatter analysis as
described previously [23]. Briefly, cells were harvested, washed with
PBS, and resuspended in hypotonic buffer containing 50 μg/ml
propidium iodide, 0.1% sodium citrate, and 0.4% Triton X-100. The
amount of hypodiploid DNA (sub-G1 fraction) was determined by
FACS analysis. For microscopy of apoptotic cells, cells were collected
by centrifugation (5 minutes at 600 rpm) and stained with 0.02%
diamidine phenylindole dihydrochloride (Roche Diagnostics, Mannheim,
Germany) in methanol for 5 minutes to stain nuclear DNA. Pictures
were taken using an Olympus AX70 “Provis” microscope (Hamburg,
Germany). Necrotic cell death was determined by measuring loss of
plasma membrane integrity by propidium iodide–emitted fluores-
cence and flow cytometry. Briefly, cells were harvested, washed with
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PBS, and resuspended in propidium iodide–containing PBS (1 μg/ml
propidium iodide).
Statistical Analysis
Statistical significance was assessed by Student’s t test (two-tailed
distribution, two-sample, unequal variance). The interaction between
Smac mimetic and TNFα was analyzed by the combination index (CI)
method using CalcuSyn software (Biosoft, Cambridge, UK). Combina-
tion index less than 0.9 indicates synergism; 0.9 to 1.1, additivity; and
greater than 1.1, antagonism.
Results
On the basis of our recent findings that IAP inhibitors bypass Bcl-2–
conferred resistance to TRAIL-induced apoptosis [17,18], we inves-
tigated in the present study whether the Smac mimetic BV6 that
neutralizes XIAP, cIAP1, and cIAP2 can overcome apoptosis resis-
tance owing to defects in the death receptor pathway.
Figure 1. Smac mimetic sensitizes FADD- or caspase-8–deficient cells for TNFα-induced cell death. (A) WT (white bars), FADD-deficient
(light gray bars), caspase-8–deficient (dark gray bars), or caspase-8–deficient and Bcl-2–overexpressing (black bars) Jurkat cells were
pretreated with BV6 (1 μM, 2 hours) before being stimulated with 1 ng/ml TNFα for 4 hours. (B) WT (closed symbols) or FADD-deficient
(open symbols) Jurkat cells were pretreated with BV6 (1 μM, 2 hours) before being stimulated with 1 ng/ml TNFα for indicated times. (C)
FADD-deficient (left panel) or WT (right panel) Jurkat cells were pretreated for 2 hours with indicated concentrations of BV6 (white bars
indicate 0 μM; light gray bars, 0.1 μM; dark gray bars, 1 μM; black bars, 3 μM) before adding the indicated concentrations of TNFα for
24 hours. (D) Primary leukemic blasts from three different children with ALL before the onset of chemotherapy were treated with 100 ng/ml
TNFα and/or 100 nM BV6 or dimethyl sulfoxide (DMSO). In A to C, cell death was analyzed by PI staining; and in D, by forward side scatter
analysis. In A to C, data are the mean and SD of at least three independent experiments performed in triplicate. **P< .001 comparing cells
treated with BV6 and TNFα compared with DMSO-treated cells. In D, data are the mean of one experiment performed in duplicate.
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Smac Mimetic Sensitizes Apoptosis-Resistant Leukemia Cells
for TNFα-Induced Cell Death
As models for defective death receptor–mediated apoptosis, we used
the T-ALL leukemia cell line Jurkat and several variants with deficien-
cies in key molecules of the death receptor pathway, namely, FADD-
deficient cells, caspase-8–deficient cells and caspase-8–deficient cells
that also overexpress Bcl-2.
To investigate whether the antagonism of IAP proteins by Smac
mimetic sensitizes leukemia cells for cell death, we preincubated cells
for 2 hours with the Smac mimetic to downregulate cIAP1/2 expres-
sion levels (Figure W1), followed by stimulation with TNFα. Inter-
estingly, Smac mimetic significantly enhanced TNFα-induced cell
death in FADD-deficient cells, caspase-8–deficient cells, as well as
caspase-8–deficient and Bcl-2–overexpressing cells rapidly within
4 hours (Figure 1A). By comparison, WT cells did not respond to
the combination treatment at this time point (Figure 1A). Impor-
tantly, kinetic analysis revealed that Smac mimetic– and TNFα-
induced cell death occurred more rapidly in FADD-deficient cells
compared with WT cells (Figure 1B). Dose titration studies showed
that nanomolar concentrations of Smac mimetic sensitized FADD-
deficient cells for TNFα-induced cell death (Figure 1C ). Calculation
of CI revealed that the interaction of Smac mimetic plus TNFα is
strongly synergistic (Table 1). Of note, equimolar concentrations
of Smac mimetic were even more effective in increasing TNFα-
mediated cell death in FADD-deficient cells than in WT cells
(Figure 1C , e.g., for 0.3 ng/ml TNFα and 0.1 μM BV6). Also,
TNFα as single agent triggered cell death at higher concentrations
in FADD-deficient cells in a dose-dependent manner (Figure W2).
Table 1. Synergistic Induction of Cell Death by BV6 and TNFα.







Combination index was calculated as described in Materials and Methods for cell death induced by
combined treatment of Jurkat FADD−/− cells for 24 hours with indicated concentrations of BV6
and TNFα. CI values of 0.1 to 0.3 indicate strong synergism.
Figure 2. FADD-deficient cells remain resistant to CD95-induced
cell death even in the presence of Smac mimetic. FADD-deficient,
caspase-8–deficient, or caspase-8–deficient and Bcl-2–overexpressing
Jurkat cells (A) orWT (B) Jurkat cells were pretreated with BV6 (1 μM,
2 hours, black bars) before stimulating for 72 hours with 0.4 ng/ml
agonistic anti-CD95 (A) or indicated concentrations of agonistic anti-
CD95 (B). Cell death was analyzed by PI staining. Data are the mean
and SD of three independent experiments performed in triplicate.
Figure 1. (continued).
974 Smac Mimetic Primes for TNFα-Induced Necroptosis Laukens et al. Neoplasia Vol. 13, No. 10, 2011
Figure 3. Lack of DNA fragmentation in Smac mimetic– and TNFα-induced cell death in FADD-deficient cells. (A) Nuclear morphology
was assessed by diamidine phenylindole dihydrochloride staining and fluorescence microscopy. FADD-deficient cells (a–d): (a) DMSO,
(b) treatment with 1 μM BV6 for 8 hours, (c) treatment with 1 ng/ml TNFα for 8 hours, and (d) pretreatment with 1 μM BV6 for 2 hours
before 8 hours of stimulation with 1 ng/ml TNFα for 8 hours. WT cells (e–h): (e) DMSO, (f) treatment with 1 μM BV6 for 8 hours, (g)
treatment with 1 ng/ml TNFα for 8 hours, and (h) pretreatment with 1 μM BV6 for 2 hours before 8 hours of stimulation with 1 ng/ml
TNFα for 8 hours. Representative pictures are shown; magnification, ×60. (B) FADD-deficient and WT Jurkat cells were pretreated with
BV6 (1 μM, 2 hours) before being stimulated with 1 ng/ml TNFα for 4 hours. DNA fragmentation was analyzed by FACS analysis of DNA
fragmentation of propidium iodide–stained nuclei. Quantitative analysis of three independent experiments performed in triplicate with
mean and SD (upper panel) and representative histograms of flow cytometric analysis (lower panel) are shown.
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Importantly, Smac mimetic also cooperated with TNFα to trigger
cell death in primary leukemic blasts (Figure 1D), highlighting the
potential clinical relevance.
To explore whether the Smac mimetic primes FADD- or caspase-
8–deficient cells also to other death receptor ligands besides TNFα,
we extended these experiments to agonistic anti-CD95 antibodies.
In contrast to the synergism of Smac mimetic and TNFα, FADD- or
caspase-8–deficient cells remained completely resistant to CD95-
induced cell death even in the presence of Smac mimetic (Figure 2A).
By comparison, Smac mimetic substantially enhanced CD95-induced
cell death in WT Jurkat cells (Figure 2B).
Together, this set of experiments demonstrates that the Smac mimetic
BV6 synergizes with TNFα to rapidly and efficiently trigger cell death
in apoptosis-resistant leukemia cells that lack essential components of
the death receptor pathway such as FADD or caspase-8.
Smac Mimetic and TNFα Induce Nonapoptotic Cell Death
in Apoptosis-Resistant Cells
Because we observed differences in the kinetic and the efficacy of
cell death induction by Smac mimetic and TNFα between WT and
FADD-deficient cells, we examined in more detail the molecular
mechanisms of cell death. The analysis of nuclear morphology revealed
that Smac mimetic and TNFα trigger nuclear condensation without
signs of fragmentation in FADD-deficient cells, whereas fragmented
nuclei, a characteristic feature for apoptotic cells, were detected in
WT cells (Figure 3A). Consistently, the assessment of DNA frag-
mentation by FACS analysis of propidium iodide–stained nuclei in
permeabilized cells showed that Smac mimetic and TNFα caused little
DNA fragmentation in FADD-deficient cells compared with a marked
increase in fragmented DNA inWT cells (Figure 3B). Furthermore, we
determined activation of caspases as another biochemical hallmark of
apoptosis. To this end, different time points were chosen for FADD-
deficient and WT cells because of the more rapid induction of cell
death in FADD-deficient cells (Figure 1B). Interestingly, no caspase
cleavage fragments were detected on treatment with Smac mimetic
and TNFα in FADD- or caspase-8–deficient cells (Figure 4). In con-
trast, Smac mimetic cooperated with TNFα to induce cleavage of
caspase-8, -3, and -9 in WT cells (Figure 4). The slight increase in
caspase-3 cleavage on treatment with BV6 alone in WT cells (Figure 4)
is consistent with the slight induction of cell death by BV6 in these
cells (Figure 1C). Together, this set of experiments demonstrates that
Smac mimetic and TNFα cooperate to trigger typical apoptotic
events such as caspase activation and DNA fragmentation in WT cells,
whereas all these characteristic features of apoptosis are lacking in
FADD-deficient cells. This points to a nonapoptotic mode of cell death
in FADD-deficient cells on exposure to Smac mimetic and TNFα.
Figure 4. Lack of caspase activation in Smac mimetic– and TNFα-
induced cell death in FADD- or caspase-8–deficient cells. FADD- or
caspase-8–deficient and WT Jurkat cells were pretreated with BV6
(1 μM, 2 hours) before being stimulated with 1 ng/ml TNFα for in-
dicated time points. Caspase activation was analyzed by Western
blot. Cleavage fragments are indicated by arrows. β-Actin served
as loading control. Asterisk indicates an unspecific band. A repre-
sentative experiment of two is shown.
Figure 5. Constitutive and TNFα-induced RIP1 ubiquitination is re-
duced by Smacmimetic exposure. Jurkat cells were pretreated with
BV6 (1 μM, 2 hours) before stimulated for 5 minutes with 2 μg/ml
Flag-tagged TNFα (A) or 50 ng/ml TNFα (B). RIP1 ubiquitination
was analyzed by immunoprecipitating TNFR1 using anti-Flag anti-
body (A) or by immunoprecipitating RIP1 followed by Western
blot analysis.
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Smac Mimetic and TNFα Act in Concert to Trigger
RIP1-Dependent Necroptosis
Because cIAP1 and cIAP2 were recently identified as E3 ubiquitin
ligases of RIP1 [10,11], we investigated whether pretreatment with
Smac mimetic results in reduced ubiquitination of RIP1 by immuno-
precipitating either TNFR1 or RIP1. Stimulation of cells with Flag-
tagged TNFα followed by immunoprecipitation of TNFR1 revealed
that exposure to Smac mimetic impaired the TNFα-induced ubiqui-
tination of RIP1 (Figure 5A). Similarly, immunoprecipitation of
RIP1 showed that Smac mimetic markedly reduced constitutive as
well as TNFα-stimulated RIP1 ubiquitination (Figure 5B). Together,
these experiments demonstrate that Smac mimetic reduces ubiquiti-
nation of RIP1.
Next, we asked whether down-regulation of cIAP1 and cIAP2 by
Smac mimetic may facilitate RIP1-dependent cell death. To address
this question, we used necrostatin 1, a specific small-molecule inhib-
itor of RIP1 [24,25]. Strikingly, Smac mimetic– and TNFα-triggered
cell death was completely blocked by the addition of necrostatin 1 in
FADD-deficient cells (Figure 6A). In contrast, necrostatin 1 caused
only a minor reduction in Smac mimetic– and TNFα-induced cell
death in WT cells (Figure 6B). To investigate the functional require-
ment of caspases for cell death induction, we used the broad-range
caspase inhibitor zVAD.fmk. Notably, the addition of zVAD.fmk
failed to confer protection against Smac mimetic– and TNFα-triggered
cell death in FADD-deficient cells, whereas zVAD.fmk significantly
reduced cell death in WT cells (Figure 6, A and B). Interestingly, this
protective effect of zVAD.fmk inWT cells was further enhanced by the
combined use of zVAD.fmk and necrostatin 1 (Figure 6B). This indicates
that RIP1-dependent cell death is initiated in WT cells under conditions
where caspase activation is inhibited. Similar to FADD-deficient cells, the
addition of necrostatin 1 profoundly reduced the Smac mimetic– and
TNFα-induced cell death also in caspase-8–deficient cells as well as in
Figure 6. Requirement of RIP1 for Smac mimetic– and TNFα-induced cell death in FADD- and caspase-8–deficient cells. FADD-deficient
(A) and WT (B) caspase-8–deficient (C) or caspase-8–deficient and Bcl-2–overexpressing (D) Jurkat cells were pretreated with BV6 (1 μM,
2 hours) before being stimulated with 1 ng/ml TNFα for 24 hours in the presence or absence of 20 μM zVAD.fmk or 30 μM necrostatin 1.
Treatment with 1 ng/ml agonistic anti-CD95 for 24 hours was used as a positive control for apoptosis. Cell death was analyzed by PI staining.
Data are the mean and SD of three independent experiments performed in triplicate. *P < .05. **P < .001.
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caspase-8–deficient and Bcl-2–overexpressing cells, whereas zVAD.fmk
failed to block cell death induction in these cells (Figure 6, C and D).
Together, these findings demonstrate that Smac mimetic and TNFα
trigger two distinct cell death programs in Jurkat cells in a context-
dependent manner: In FADD- or caspase-8–deficient Jurkat cells, Smac
mimetic and TNFα induce RIP1-dependent and caspase-independent
necroptosis, whereas they trigger caspase-dependent apoptotic cell
death in WT Jurkat cells.
Discussion
In the present study, we identify a novel mechanism of how Smac
mimetics can bypass apoptosis resistance of leukemia cells by dem-
onstrating that the Smac mimetic BV6 promotes TNFα-induced
necroptosis as an alternative cell death program in apoptosis-resistant
cells that lack essential molecules of the death receptor pathway such
as FADD or caspase-8. Thus, Smac mimetic can prime leukemia cells
to either apoptotic or necroptotic cell death after exposure to TNFα,
depending on the cellular context and the presence and functionality
of key signaling molecules.
In the presence of FADD and caspase-8 (i.e., in WT Jurkat cells),
Smac mimetic enhances TNFα-induced apoptosis. Apoptotic cell
death is demonstrated by several characteristic features, including
caspase activation, DNA fragmentation, and inhibition of cell death
by the caspase inhibitor zVAD.fmk. In contrast, in the absence of
either FADD or caspase-8, Smac mimetic primes cells for TNFα-
initiated necroptosis that critically depends on RIP1 and lacks proto-
typic features of apoptosis. Thus, in apoptosis-resistant cells, which
are devoid of signaling molecules that are critically required for death
receptor–induced apoptosis such as FADD or caspase-8, Smac
mimetic in combination with TNFα activates RIP1-dependent
necroptosis as an alternative cell death program to ensure the demise
of the cell. Necroptotic cell death is confirmed by pharmacological
inhibition of RIP1, a critical mediator of necroptosis [4], by bio-
chemical features (i.e., lack of caspase activation, insensitivity to the
caspase inhibitor zVAD.fmk) as well as by morphologic characteristics
(i.e., nuclear condensation without fragmentation). Of note, Smac
mimetic– and TNFα-induced necroptosis occurs in a highly synergis-
tic manner, as calculated by CI. Consistently, we recently reported in a
murine prototypic model of necrosis that depletion of cIAP1 by Smac
mimetic sensitizes L929 cells for TNFα-mediated necroptosis that crit-
ically depends on RIP1 [26].
Cell death and survival pathways share some common central
components, for example, the serine/threonine kinase RIP1 [4].
Whereas stimulation with TNFα in the absence of Smac mimetic
causes little cell death in WT and FADD-deficient Jurkat cells, con-
sistent with TNFα triggering ubiquitination of RIP1 and nuclear factor
κB activation in the presence of cIAP proteins [7], Smac mimetic–
mediated degradation of cIAP proteins switches TNFα-stimulated sur-
vival toward cell death (Figure 6). Cell death proceeds either via the
apoptotic pathway, if FADD or caspase-8 are present (i.e., in WT
Jurkat cells), or alternatively via the necroptotic pathway in the absence
of FADD or caspase-8 (i.e., in FADD- or caspase-8–deficient Jurkat
cells) (Figure 6). In WT Jurkat cells, RIP1 may be involved in mediat-
ing either apoptosis or necroptosis, depending on the cellular context.
When caspase activation occurs, RIP1 may contribute to some extent
to the induction of apoptosis on treatment with Smac mimetic and
TNFα via the formation of a cytosolic complex containing RIP1/
FADD/caspase-8. This conclusion is supported by our data showing
that the RIP1 inhibitor necrostatin 1 slightly reduces Smac mimetic–
and TNFα-induced cell death also in WT Jurkat cells in the absence of
the caspase inhibitor zVAD.fmk. When caspase activation is blocked in
WT Jurkat cells, Smac mimetic– and TNFα-induced cell death may
proceed via the necroptotic route. In line with this notion, we found
that the partial protection against Smac mimetic– and TNFα-induced
cell death by the caspase inhibitor zVAD.fmk in WT Jurkat cells is
further enhanced by RIP1 inhibition. This could be explained by a
switch from Smac mimetic– and TNFα-induced apoptosis toward
necroptosis on caspase inhibition by zVAD.fmk, which is inhibited
by necrostatin 1. Induction of necrosis on caspase inhibition has pre-
viously been shown for the CD95 pathway [27,28]. However, the
absence of Smac mimetic–mediated sensitization to CD95-triggered
apoptosis in FADD-deficient leukemia cells in our study may suggest
that other E3 ubiquitin ligases than cIAP proteins are involved in ubiqui-
tination of RIP1 possibly in a stimulus-dependent manner, thereby pre-
venting RIP1 to signal to necroptosis. Support for this hypothesis comes
from a recent report showing that the E3 ubiquitin ligase Peli1 is required
for RIP1 ubiquitination during Toll-like receptor 3 signaling [29].
Together, our results demonstrate that apoptotic and necroptotic cell
death pathways are more closely interlinked than previously thought.
The novelty and relevance of our findings is underscored by recent evi-
dence of a close crosstalk between different cell death pathways. Accord-
ingly, key components of the extrinsic apoptosis pathway including
FADD and caspase-8 were shown to exert also nonapoptotic functions
by preventing programmed necrosis [30–32]. Interestingly, we found
that Smac mimetic– and TNFα-induced necroptosis occurs even more
rapidly in FADD- or caspase-8–deficient cells compared with Smac
mimetic– and TNFα-induced apoptosis in WT cells at equimolar con-
centrations, consistent with a more rapid kinetic of necroptotic cell death.
In addition, Smac mimetic and TNFα induce necroptosis more rapidly
in caspase-8–deficient cells with Bcl-2 overexpression compared with
caspase-8–deficient cells without Bcl-2 overexpression, consistent with
the notion that inhibition of apoptosis may favor necroptosis.
Our findings have several important implications. By demonstrat-
ing that Smac mimetic sensitizes cells that lack essential molecules of
the death receptor pathway such as FADD or caspase-8 for TNFα-
induced necroptosis as an alternative cell death program, these data
provide first evidence that Smac mimetic can overcome resistance to
TNFα-induced apoptosis. This mechanism might be relevant in
cancers with local autocrine or paracrine production of TNFα, for
example, in inflammatory cancers, because Smac mimetic–mediated
down-regulation of cIAPs might switch the TNFα response from
survival toward cell death. Against the background of our previous
reports showing that small-molecule inhibitors of IAP proteins prime
childhood ALL cells for TRAIL- or CD95-induced apoptosis
[18,33], the current study identifies a novel molecular mechanisms
of inhibitors of IAP proteins for bypassing apoptosis resistance in
pediatric acute leukemia. Moreover, there is recent evidence in
childhood ALL that induction of necroptosis can bypass resistance
to glucocorticoids, one of the key drugs used in the clinic for child-
hood leukemia [34]. This underscores the potential clinical relevance
of necroptosis as a new therapeutic strategy in refractory pediatric
ALL. Taken together, Smac mimetics represent a promising novel
approach to promote necroptosis as an alternative cell death program
in apoptosis-resistant cancers, which warrants further investigation.
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Figure W1. Down-regulation of IAP proteins by Smac mimetic. WT
Jurkat cells were treated with 1 μM BV6 for 2 hours. Protein ex-
pressions of cIAP1, cIAP2, XIAP, and survivin were analyzed by
Western blot. β-Actin served as loading control.
Figure W2. Dose-response of TNFα-induced cell death. WT (white
bars) or FADD-deficient (black bars) Jurkat cells were treated with
the indicated concentrations of TNFα for 24 hours. Cell death was
analyzed by PI staining. Data are the mean and SD of three inde-
pendent experiments performed in triplicate.
